Agile Therapeutics (AGRX)
Oppenheimer analyst Leland Gershell assigned a Buy rating to Agile Therapeutics today and set a price target of $10.00. The company’s shares closed last Monday at $3.02.
According to TipRanks.com, Gershell is a 5-star analyst with an average return of 20.1% and a 51.4% success rate. Gershell covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Viridian Therapeutics, and CASI Pharmaceuticals.
Currently, the analyst consensus on Agile Therapeutics is a Strong Buy with an average price target of $8.50.
Athenex received a Hold rating from Oppenheimer analyst Kevin DeGeeter today. The company’s shares closed last Monday at $5.46, close to its 52-week low of $5.24.
According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 59.2% and a 59.9% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Sensei Biotherapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Athenex with a $7.75 average price target, implying a 42.2% upside from current levels. In a report released yesterday, Needham also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.